Initial clinical experience with I-131-humanized LL2 (I-131-hLL2) anti-CD22 MAb against B-cell malignancies.

JOURNAL OF NUCLEAR MEDICINE(1998)

Cited 0|Views7
No score
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined